Award Data

Blood-based point-of-care (POC) diagnostics or remote diagnostics that require specialized equipment only available in centralized, commercial laboratories are currently limited by major logistical and technical barriers. Blood collection can be a traumatic, inconvenient, and inconsistent process that is based on decades-old technologies, such as the lancet-puncture, that are not amenable to new P ...

DESCRIPTION (provided by applicant): The goal of this Type 2 Competitive Renewal SBIR application to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is to conduct a phase I/II clinical trial to investigate the safety and earlyefficacy of a novel antimicrobial living human skin substitute for the treatment of a life-threatening complication of diabetes: chronic, nonhea ...

DESCRIPTION (provided by applicant): The goal of this research is develop therapeutic products for Cryptosporidium parvum which can be made at a scale and cost which are feasible for delivery to large populations of patients or individuals at risk, as may be necessary in countering bioterrorism, or in protecting field-deployed armed forces. Our approach is to develop recombinant neutralizing mon ...

DESCRIPTION (provided by applicant): Over 1.1 million conceptuses and fetuses die spontaneously each year, nearly 28,000 after 20 weeks' gestation. 12.5% of all infants are delivered prematurely, and the cost of care for the prematurely born is nearly 27 billion dollars annually. Prenatal assessment is currently dominated by ultrasound-based techniques; however, these are limited in their ability ...

DESCRIPTION (provided by applicant): Chronic and infected wounds significantly affect the quality of life for millions of US citizens and are associated with increased risk of complications including the devastating consequence of amputation. As of 2006, infections of diabetic foot ulcers resulted in 82,000 amputations each year and it has been estimated that these numbers will increase by 10% ann ...

DESCRIPTION (provided by applicant): Xenotransplantation with pig organs offers the best near term hope for satisfying the limitation imposed by shortage of human organs. This research project is directed toward producing as a product a genetically modified pig that will be the best potential donor for xenotransplants to humans. Although hyperacute rejection of pig organs in primate recipients ...

Scarab Genomics has established a unique, tiny footprint, extended bacterial fermentation process enabled by its reduced genome E. coli, for production of protein therapeutics, especially vaccine conjugates. The process will massively reduce the cost and upgrade the quality of these critical vaccine components. This Phase IIB resubmission focuses on commercial development of Scarab’s first vacci ...

DESCRIPTION (provided by applicant): Cryptosporidiosis is a leading cause of diarrheal disease worldwide and is a category B biothreat agent. Two major species, Cryptosporidium hominis and Cryptosporidium parvum are responsible for over ninety percent of cases in man. C. parvum is zoonotic, with a reservoir in cattle, where it is an economically important cause of disease. There is currently no sp ...

Therapeutic monoclonal antibodies bind to specific regions of proteins called epitopes, which elicit cellular responses that treat or cure disease. Discovering therapeutic antibodies traditionally requires laborious and expensive screening experiments, so computational approaches that select which antibodies bind an epitope best and have the most desirable pharmaceutical properties are in high dem ...

Scarab Genomics’ C-Flow™ technology is a highly efficient continuous culture system that can produce kilograms of protein in a few weeks at a mere 10-liter scale. This project will determine whether C-Flow can be further developed as an efficient system for production of single-chain antibody therapeutics. Antibody fragments, especially single-chain variants, are increasingly important for dia ...